US 11,897,851 B2
Heterocyclic GLP-1 agonists
Qinghua Meng, Shanghai (CN); Hui Lei, Shanghai (CN); Haizhen Zhang, Shanghai (CN); Xichen Lin, Shanghai (CN); and Andrew Jennings, South San Francisco, CA (US)
Assigned to Gasherbrum Bio, Inc., South San Francisco, CA (US)
Filed by Gasherbrum Bio, Inc., South San Francisco, CA (US)
Filed on Feb. 6, 2023, as Appl. No. 18/106,378.
Application 18/106,378 is a continuation of application No. PCT/CN2021/111193, filed on Aug. 6, 2021.
Prior Publication US 2023/0192633 A1, Jun. 22, 2023
Int. Cl. C07D 273/01 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01)
CPC C07D 273/01 (2013.01) [A61K 9/0053 (2013.01); A61K 45/06 (2013.01)] 5 Claims
 
1. A compound of Formula (I-A4-1), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
custom character is a single bond or a double bond;
R0-1 is selected from the group consisting of hydrogen and (C1-C3)alkyl;
X4 is selected from the group consisting of N and CRy;
Ry is selected from the group consisting of hydrogen, —OH, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, CN, and halogen;
T2 is (C1-C3)alkyl which is substituted with a substituent selected from the group consisting of (C1-C3)alkoxy, S(O)2(C1-C3 alkyl), (C3-C6)cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl, wherein the phenyl or 5- to 6-membered heteroaryl are each optionally substituted with halogen or (C1-C3)alkyl;
Raa is selected from the group consisting of hydrogen and (C1-C3)alkyl;
Ring C is selected from the group consisting of phenyl and 6-membered heteroaryl;
b is 0, 1, or 2; and
each occurrence of Rb is independently selected from the group consisting of (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, and CN.